PMID- 30753810
OWN - NLM
STAT- MEDLINE
DCOM- 20190329
LR  - 20190329
IS  - 1872-7786 (Electronic)
IS  - 0009-2797 (Linking)
VI  - 302
DP  - 2019 Apr 1
TI  - Suppressive effects of pelargonidin on lipopolysaccharide-induced inflammatory 
      responses.
PG  - 67-73
LID - S0009-2797(18)30956-6 [pii]
LID - 10.1016/j.cbi.2019.02.007 [doi]
AB  - Pelargonidin (PEL) is a well-known red pigment found in plants, and has been 
      reported as having important biological activities that are potentially 
      beneficial for human health. Here, we tested the possible use of PEL in the 
      treatment of lipopolysaccharide (LPS)-mediated vascular inflammatory responses. 
      The anti-inflammatory activities of PEL were determined by measuring 
      permeability, neutrophils adhesion and migration, and activation of 
      pro-inflammatory proteins in LPS-activated human umbilical vein endothelial cells 
      (HUVECs) and mice. We found that PEL inhibited LPS-induced barrier disruption, 
      expression of cell adhesion molecules (CAMs), and adhesion/transendothelial 
      migration of neutrophils to human endothelial cells. PEL also suppressed 
      LPS-induced hyperpermeability and leukocytes migration in vivo. Furthermore, PEL 
      suppressed the production of tumor necrosis factor-alpha (TNF-alpha) or Interleukin 
      (IL)-6 and the activation of nuclear factor-kappaB (NF-kappaB) or extracellular regulated 
      kinases (ERK) 1/2 by LPS. Moreover, treatment with PEL resulted in reduced 
      LPS-induced lethal endotoxemia. These results suggest that PEL possesses 
      anti-inflammatory functions by inhibiting hyperpermeability, expression of CAMs, 
      and adhesion and migration of leukocytes, thereby endorsing its usefulness as a 
      therapy for vascular inflammatory diseases.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Lee, Bong-Seon
AU  - Lee BS
AD  - College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, BK21 
      Plus KNU Multi-Omics Based Creative Drug Research Team, Kyungpook National 
      University, Daegu, 41566, Republic of Korea.
FAU - Lee, Changhun
AU  - Lee C
AD  - College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, BK21 
      Plus KNU Multi-Omics Based Creative Drug Research Team, Kyungpook National 
      University, Daegu, 41566, Republic of Korea.
FAU - Yang, Sumin
AU  - Yang S
AD  - College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, BK21 
      Plus KNU Multi-Omics Based Creative Drug Research Team, Kyungpook National 
      University, Daegu, 41566, Republic of Korea.
FAU - Park, Eui Kyun
AU  - Park EK
AD  - Department of Pathology and Regenerative Medicine, School of Dentistry, Kyungpook 
      National University, Daegu, 41940, Republic of Korea.
FAU - Ku, Sae-Kwang
AU  - Ku SK
AD  - Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany 
      University, Gyeongsan, 38610, Republic of Korea. Electronic address: 
      gucci200@hanmail.net.
FAU - Bae, Jong-Sup
AU  - Bae JS
AD  - College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, BK21 
      Plus KNU Multi-Omics Based Creative Drug Research Team, Kyungpook National 
      University, Daegu, 41566, Republic of Korea. Electronic address: baejs@knu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20190210
PL  - Ireland
TA  - Chem Biol Interact
JT  - Chemico-biological interactions
JID - 0227276
RN  - 0 (Anthocyanins)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 7690-51-9 (pelargonidin)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Animals
MH  - Anthocyanins/*pharmacology/therapeutic use
MH  - Anti-Inflammatory Agents/*pharmacology/therapeutic use
MH  - Cell Adhesion/*drug effects
MH  - Cell Adhesion Molecules/metabolism
MH  - Cell Movement/drug effects
MH  - Endotoxemia/drug therapy/pathology
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Interleukin-6/metabolism
MH  - Leukocytes/cytology/drug effects/metabolism
MH  - Lipopolysaccharides/*toxicity
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/metabolism
MH  - Permeability/drug effects
MH  - Toll-Like Receptor 4/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
OTO - NOTNLM
OT  - Barrier integrity
OT  - Inflammation
OT  - Lipopolysaccharide
OT  - Pelargonidin
EDAT- 2019/02/13 06:00
MHDA- 2019/03/30 06:00
CRDT- 2019/02/13 06:00
PHST- 2018/07/22 00:00 [received]
PHST- 2019/02/06 00:00 [revised]
PHST- 2019/02/08 00:00 [accepted]
PHST- 2019/02/13 06:00 [pubmed]
PHST- 2019/03/30 06:00 [medline]
PHST- 2019/02/13 06:00 [entrez]
AID - S0009-2797(18)30956-6 [pii]
AID - 10.1016/j.cbi.2019.02.007 [doi]
PST - ppublish
SO  - Chem Biol Interact. 2019 Apr 1;302:67-73. doi: 10.1016/j.cbi.2019.02.007. Epub 
      2019 Feb 10.